Ewa Chmielowska

4.4k total citations
44 papers, 468 citations indexed

About

Ewa Chmielowska is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Ewa Chmielowska has authored 44 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Ewa Chmielowska's work include Cancer Treatment and Pharmacology (10 papers), Lung Cancer Treatments and Mutations (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Ewa Chmielowska is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Lung Cancer Treatments and Mutations (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Ewa Chmielowska collaborates with scholars based in Poland, United Kingdom and Italy. Ewa Chmielowska's co-authors include E Krykowski, Piotr Smolewski, Maria Błasińska-Morawiec, A Płużańska, Tadeusz Robak, James A. Williams, Eveline Nüesch, Sabine Lauer, Ірина Давиденко and Burkhard Otremba and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Ewa Chmielowska

40 papers receiving 462 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ewa Chmielowska Poland 12 251 132 119 109 70 44 468
Rossella De Cecio Italy 17 393 1.6× 248 1.9× 95 0.8× 171 1.6× 34 0.5× 47 706
Anna Maria Mosconi Italy 13 364 1.5× 90 0.7× 59 0.5× 140 1.3× 136 1.9× 39 558
Öznur Bal Türkiye 12 175 0.7× 142 1.1× 76 0.6× 78 0.7× 16 0.2× 49 380
Emi Noguchi Japan 12 352 1.4× 208 1.6× 61 0.5× 115 1.1× 24 0.3× 63 608
Don W. Shaffer United States 8 407 1.6× 151 1.1× 273 2.3× 138 1.3× 38 0.5× 11 678
U. Matulonis United States 9 342 1.4× 252 1.9× 93 0.8× 125 1.1× 122 1.7× 33 596
Alejandro Yovine France 11 422 1.7× 428 3.2× 104 0.9× 126 1.2× 47 0.7× 24 732
Luigi Salvagno Italy 15 270 1.1× 119 0.9× 254 2.1× 115 1.1× 43 0.6× 46 618
Richard D. Drake United States 15 159 0.6× 109 0.8× 73 0.6× 155 1.4× 336 4.8× 20 716
Mojca Persic United Kingdom 6 147 0.6× 70 0.5× 93 0.8× 103 0.9× 167 2.4× 12 345

Countries citing papers authored by Ewa Chmielowska

Since Specialization
Citations

This map shows the geographic impact of Ewa Chmielowska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ewa Chmielowska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ewa Chmielowska more than expected).

Fields of papers citing papers by Ewa Chmielowska

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ewa Chmielowska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ewa Chmielowska. The network helps show where Ewa Chmielowska may publish in the future.

Co-authorship network of co-authors of Ewa Chmielowska

This figure shows the co-authorship network connecting the top 25 collaborators of Ewa Chmielowska. A scholar is included among the top collaborators of Ewa Chmielowska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ewa Chmielowska. Ewa Chmielowska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
André, Thierry, Alfredo Falcone, Yaroslav Shparyk, et al.. (2023). Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study.. Journal of Clinical Oncology. 41(16_suppl). 3512–3512. 3 indexed citations
2.
Chmielowska, Ewa. (2021). Nivolumab in two cases of refractory mycosis fungoides erythroderma. Central European Journal of Immunology. 46(4). 535–538. 2 indexed citations
3.
Giebel, Sebastian, Wanda Knopińska‐Posłuszny, Ewa Chmielowska, et al.. (2021). High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma. Annals of Hematology. 100(7). 1755–1767.
4.
Kowalski, Dariusz M., Grzegorz Czyżewicz, Maciej Bryl, et al.. (2020). Effectiveness of Osimertinib in Patients with Lung Adenocarcinoma in Clinical Practice—The Expanded Drug Access Program in Poland. Advances in respiratory medicine. 88(3). 189–196. 1 indexed citations
5.
Nowikiewicz, Tomasz, et al.. (2017). Prevalence of biological types of breast cancer and their influence on disease staging and therapeutic management – a single-center study. Polish Journal of Pathology. 1(1). 16–25. 3 indexed citations
6.
Lidbrink, Elisabet, J. Erfán, Ewa Chmielowska, et al.. (2017). OHERA: A real world study of cardiac events in > 3700 patients with her2-positive early breast cancer treated with trastuzumab: Final analysis. Annals of Oncology. 28. v52–v52. 2 indexed citations
7.
Szmit, Sebastian, Wojciech Jurczak, Jan Maciej Zaucha, et al.. (2017). Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders. International Journal of Cardiology. 235. 147–153. 10 indexed citations
8.
Duchnowska, Renata, Ewa Chmielowska, Joanna Streb, et al.. (2016). The role of anthracyclines and dose dense therapy in an adjuvant setting, in HER2-positive early breast cancer, in clinical practice. Oncology in Clinical Practice. 12(1). 8–11. 1 indexed citations
9.
Oza, Amit M., Frédèric Selle, Ірина Давиденко, et al.. (2016). Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study. International Journal of Gynecological Cancer. 27(1). 50–58. 55 indexed citations
10.
Chmielowska, Ewa, et al.. (2015). Reshaping the Tradition: Postpartum Care in Modern Taiwan. 123–136. 1 indexed citations
11.
Chmielowska, Ewa, et al.. (2015). Follow-up of patients with mycosis fungoides after interferon α2b treatment failure. Advances in Dermatology and Allergology. 2(2). 67–72. 5 indexed citations
12.
13.
Sokołowska‐Wojdyło, Małgorzata, Aleksandra G. Florek, Jan Maciej Zaucha, et al.. (2014). Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma. American Journal of Therapeutics. 23(3). e749–e756. 9 indexed citations
14.
Wojtukiewicz, Marek Z., et al.. (2014). Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland. Współczesna Onkologia. 6(6). 419–424. 1 indexed citations
15.
Twelves, Chris, Ewa Chmielowska, Libor Havel, et al.. (2013). Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Annals of Oncology. 25(1). 132–138. 30 indexed citations
16.
Plummer, Ruth, Paul Lorigan, Ewan Brown, et al.. (2013). Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. British Journal of Cancer. 109(6). 1451–1459. 23 indexed citations
17.
Giebel, Sebastian, Tomasz Czerw, Maria Saduś‐Wojciechowska, et al.. (2013). Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers. Bone Marrow Transplantation. 48(7). 915–921. 17 indexed citations
18.
Chmielowska, Ewa, et al.. (2011). Liposomal doxorubicin-induced cardiotoxicity — case report. Oncology in Clinical Practice. 7(3). 152–156.
19.
Chmielowska, Ewa, et al.. (2011). Safety and efficacy of interferon-alfa2b (IFN) in the treatment of patients with mycosis fungoides. Oncology in Clinical Practice. 7(6). 301–310.
20.
Biganzoli, Laura, Zefei Jiang, Mikhail Lichinitser, et al.. (2011). First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study. Annals of Oncology. 23(1). 111–118. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rossella De Cecio Breakdown of academic impact, for papers by Anna Maria Mosconi Breakdown of academic impact, for papers by Öznur Bal Breakdown of academic impact, for papers by Emi Noguchi Breakdown of academic impact, for papers by Don W. Shaffer Breakdown of academic impact, for papers by U. Matulonis Breakdown of academic impact, for papers by Alejandro Yovine Breakdown of academic impact, for papers by Luigi Salvagno Breakdown of academic impact, for papers by Richard D. Drake Breakdown of academic impact, for papers by Mojca Persic
Rankless by CCL
2026